Michael J. Mann, MD

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Michael J. Mann, MD

Clinical Professor, Department of Surgery, UCSF

Phone: (415) 353-1606 (appts)
Box 1674, UCSF
San Francisco, CA 94143-1674

View on UCSF Profiles

Selected Publications

  1. Genistein Suppresses Growth of Human Uterine Sarcoma Cell Lines via Multiple Mechanisms. Anticancer Res. 2015 Jun; 35(6):3167-73.
    View on PubMed
  2. Prognostic molecular assay might improve identification of patients at risk for recurrence in early-stage non-small-cell lung cancer. Clin Lung Cancer. 2014 Nov; 15(6):426-32.
    View on PubMed
  3. Aggressive and minimally invasive surgery for pulmonary metastasis of sarcoma. J Thorac Cardiovasc Surg. 2014 Apr; 147(4):1193-200; discussion 1200-1.
    View on PubMed
  4. VATS lobectomy facilitates the delivery of adjuvant docetaxel-carboplatin chemotherapy in patients with non-small cell lung cancer. J Thorac Dis. 2013 Oct; 5(5):578-84.
    View on PubMed
  5. Analytical validation of a practical molecular assay prognostic of survival in nonsquamous non-small cell lung cancer. Diagn Mol Pathol. 2013 Jun; 22(2):65-9.
    View on PubMed
  6. International trial of adjuvant therapy in high risk stage I non-squamous cell carcinoma identified by a 14-gene prognostic signature. Transl Lung Cancer Res. 2013 Jun; 2(3):222-5.
    View on PubMed
  7. Prognostic assay in small, node-negative non-small cell lung cancer--reply. JAMA. 2013 Feb 27; 309(8):769-70.
    View on PubMed
  8. MEK1-induced physiological hypertrophy inhibits chronic post-myocardial infarction remodeling in mice. J Cell Biochem. 2013 Jan; 114(1):47-55.
    View on PubMed
  9. A prognostic assay to identify patients at high risk of mortality despite small, node-negative lung tumors. JAMA. 2012 Oct 24; 308(16):1629-31.
    View on PubMed
  10. A practical molecular assay to predict survival in resected non-squamous, non-small-cell lung cancer: development and international validation studies. Lancet. 2012 Mar 3; 379(9818):823-32.
    View on PubMed
  11. Biomimetic matrices for myocardial stabilization and stem cell transplantation. J Biomed Mater Res A. 2010 Dec 15; 95(4):1055-66.
    View on PubMed
  12. Distinctive ERK and p38 signaling in remote and infarcted myocardium during post-MI remodeling in the mouse. J Cell Biochem. 2010 Apr 15; 109(6):1185-91.
    View on PubMed
  13. Heart failure switches the RV alpha1-adrenergic inotropic response from negative to positive. Am J Physiol Heart Circ Physiol. 2010 Mar; 298(3):H913-20.
    View on PubMed
  14. Myocardial survival signaling in response to stem cell transplantation. J Am Coll Surg. 2009 Apr; 208(4):607-13.
    View on PubMed
  15. Sphingolipid signaling and treatment during remodeling of the uninfarcted ventricular wall after myocardial infarction. Am J Physiol Heart Circ Physiol. 2009 Apr; 296(4):H1193-9.
    View on PubMed
  16. Surgical ventricular reconstruction in mice: elucidating potential targets for combined molecular/surgical intervention. J Thorac Cardiovasc Surg. 2009 Apr; 137(4):942-9.
    View on PubMed
  17. Cardiac transgenic matrix metalloproteinase-2 expression induces myxomatous valve degeneration: a potential model of mitral valve prolapse disease. Cardiovasc Pathol. 2009 Sep-Oct; 18(5):253-61.
    View on PubMed
  18. National Institutes of Health funding for cardiothoracic surgical research. J Thorac Cardiovasc Surg. 2008 Aug; 136(2):392-7; discussion 398-9.
    View on PubMed
  19. National institutes of health funding for surgical research. Ann Surg. 2008 Feb; 247(2):217-21.
    View on PubMed
  20. Transcription factor decoys: a new model for disease intervention. Ann N Y Acad Sci. 2005 Nov; 1058:128-39.
    View on PubMed

Go to UCSF Profiles, powered by CTSI